

## Product datasheet for **TL308738V**

### Osteoprotegerin (TNFRSF11B) Human shRNA Lentiviral Particle (Locus ID 4982)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Osteoprotegerin (TNFRSF11B) Human shRNA Lentiviral Particle (Locus ID 4982)
Locus ID:	4982
Synonyms:	OCIF; OPG; PDB5; TR1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	TNFRSF11B - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">BC030155</a> , <a href="#">NM_002546</a> , <a href="#">NM_002546.1</a> , <a href="#">NM_002546.2</a> , <a href="#">NM_002546.3</a> , <a href="#">BC011023</a> , <a href="#">BM748946</a> , <a href="#">NM_002546.4</a>
UniProt ID:	<a href="#">O00300</a>
Summary:	The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).